Upexi, Inc. Q2 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy UPXI?
Source: seekingalpha
- Financial Performance Overview: Upexi reported total revenue of approximately $8.1 million for Q2, an increase of about $4 million year-over-year, despite a net loss of approximately $178.9 million primarily due to unrealized losses on digital assets and stock compensation expenses, indicating financial pressure amid market volatility.
- Asset Management Strategy: CEO Allan Marshall emphasized that despite a 40% drop in Solana prices, the company plans to enhance its valuation by increasing Solana token holdings and yields, demonstrating a commitment to stability in uncertain markets.
- Market Risk Mitigation: Management identified market volatility and declining Solana prices as key risks impacting quarterly results, with Marshall mentioning mergers and asset sales as potential mitigants, reflecting the company's adaptive strategies in the face of challenges.
- Future Outlook: Although no specific earnings guidance was provided, management remains optimistic about Solana's long-term potential, planning to increase the number of tokens held in treasury and boost quarterly revenue from the treasury, indicating confidence in market recovery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UPXI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UPXI
Wall Street analysts forecast UPXI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UPXI is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.050
Low
6.00
Averages
6.00
High
6.00
Current: 1.050
Low
6.00
Averages
6.00
High
6.00
About UPXI
Upexi, Inc. is a solana-focused treasury company. The Company is a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. The Company’s brands include Lucky Tail, PRAX, and Cure Mushrooms. Lucky Tail is a pet care product brand that provides products from grooming tools to nutritional products. Cure Mushrooms is a full line of medicinal mushroom products, designed by effect for consumers, which offers mushroom extracts in tinctures and gummies. PRAX is a full line of medicinal mushroom products, designed by effect for consumers, which are cultivated, extracted, and produced in the United States. Its products are distributed in the United States of America and internationally through multiple entities and managed through locations in Florida.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UPEXI Reports Q2 EPS of -$2.94
- Market Overview: The U.S. stock market is experiencing fluctuations, with the S&P 500 index showing a slight decline of 2.94 points.
- Economic Indicators: Recent economic data suggests mixed signals, impacting investor sentiment and market performance.
- Sector Performance: Various sectors are reacting differently to economic news, with some showing resilience while others struggle.
- Future Outlook: Analysts are closely monitoring upcoming economic reports that could influence market trends and investor decisions.
See More
UPEXI Reports Q2 Revenue of $8.1 Million
- Company Overview: UPEXIQ reported a revenue of USD 8.1 million for the second quarter.
- Financial Performance: The revenue reflects the company's growth and operational success during this period.
- Market Position: UPEXIQ continues to strengthen its position in the market with increasing financial results.
- Future Outlook: The company is optimistic about future performance and potential growth opportunities.
See More
UPEXI Reports Q2 Net Loss of USD 178.9 Million
- Financial Performance: UPEX reported a net income of USD 178.9 million for the second quarter.
- Comparison to Previous Period: This figure reflects a significant change compared to previous financial results, indicating growth or decline in profitability.
See More
UPEXI ANNOUNCES FINANCIAL RESULTS FOR FISCAL SECOND QUARTER 2026
Financial Performance: UPEXIRE reported its fiscal results for the second quarter of 2026, showcasing key financial metrics and performance indicators.
Revenue Trends: The report highlights trends in revenue generation, including growth areas and any declines in specific sectors.
Operational Insights: UPEXIRE provides insights into operational efficiencies and challenges faced during the quarter, impacting overall performance.
Future Outlook: The company outlines its strategic plans and expectations for the upcoming quarters, addressing market conditions and potential opportunities.
See More
UPEXI Reports Q2 Gross Profit of $6.7 Million
- Company Overview: UPEXIQ reported a gross profit of $6.7 million for the second quarter.
- Financial Performance: The financial results indicate a strong performance in the company's operations during this period.
See More
Upexi Scheduled to Announce Q2 Earnings on February 10
- Earnings Announcement Schedule: Upexi is set to release its Q2 2026 earnings on February 10 after market close, with consensus EPS estimate at -$0.07 and revenue estimate at $9.42 million, reflecting a cautious market outlook on the company's financial performance.
- EPS Estimate Changes: Over the past three months, Upexi's EPS estimates have seen no upward revisions and two downward revisions, indicating a decline in analyst confidence regarding the company's profitability, which may affect investor expectations for future performance.
- Revenue Estimate Dynamics: In contrast to EPS, revenue estimates have experienced two upward revisions with no downward adjustments during the same period, suggesting a relatively optimistic market view on Upexi's sales growth, despite ongoing challenges in overall profitability.
- Financing Activity Overview: Upexi recently entered into a $36 million Solana-backed convertible note deal with Hivemind Capital and priced a $23 million private placement offering above market price, demonstrating the company's proactive measures in strengthening its capital structure.
See More
UPEXI Reports Q2 EPS of -$2.94
- Market Overview: The U.S. stock market is experiencing fluctuations, with the S&P 500 index showing a slight decline of 2.94 points.
- Economic Indicators: Recent economic data suggests mixed signals, impacting investor sentiment and market performance.
- Sector Performance: Various sectors are reacting differently to economic news, with some showing resilience while others struggle.
- Future Outlook: Analysts are closely monitoring upcoming economic reports that could influence market trends and investor decisions.
See More
UPEXI Reports Q2 Revenue of $8.1 Million
- Company Overview: UPEXIQ reported a revenue of USD 8.1 million for the second quarter.
- Financial Performance: The revenue reflects the company's growth and operational success during this period.
- Market Position: UPEXIQ continues to strengthen its position in the market with increasing financial results.
- Future Outlook: The company is optimistic about future performance and potential growth opportunities.
See More
UPEXI Reports Q2 Net Loss of USD 178.9 Million
- Financial Performance: UPEX reported a net income of USD 178.9 million for the second quarter.
- Comparison to Previous Period: This figure reflects a significant change compared to previous financial results, indicating growth or decline in profitability.
See More
UPEXI ANNOUNCES FINANCIAL RESULTS FOR FISCAL SECOND QUARTER 2026
Financial Performance: UPEXIRE reported its fiscal results for the second quarter of 2026, showcasing key financial metrics and performance indicators.
Revenue Trends: The report highlights trends in revenue generation, including growth areas and any declines in specific sectors.
Operational Insights: UPEXIRE provides insights into operational efficiencies and challenges faced during the quarter, impacting overall performance.
Future Outlook: The company outlines its strategic plans and expectations for the upcoming quarters, addressing market conditions and potential opportunities.
See More
UPEXI Reports Q2 Gross Profit of $6.7 Million
- Company Overview: UPEXIQ reported a gross profit of $6.7 million for the second quarter.
- Financial Performance: The financial results indicate a strong performance in the company's operations during this period.
See More
Upexi Scheduled to Announce Q2 Earnings on February 10
- Earnings Announcement Schedule: Upexi is set to release its Q2 2026 earnings on February 10 after market close, with consensus EPS estimate at -$0.07 and revenue estimate at $9.42 million, reflecting a cautious market outlook on the company's financial performance.
- EPS Estimate Changes: Over the past three months, Upexi's EPS estimates have seen no upward revisions and two downward revisions, indicating a decline in analyst confidence regarding the company's profitability, which may affect investor expectations for future performance.
- Revenue Estimate Dynamics: In contrast to EPS, revenue estimates have experienced two upward revisions with no downward adjustments during the same period, suggesting a relatively optimistic market view on Upexi's sales growth, despite ongoing challenges in overall profitability.
- Financing Activity Overview: Upexi recently entered into a $36 million Solana-backed convertible note deal with Hivemind Capital and priced a $23 million private placement offering above market price, demonstrating the company's proactive measures in strengthening its capital structure.
See More
